77 results about "Nectin" patented technology

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The present invention features methods for diagnosing cancer or assessing or determining the prognosis of a patient with lung cancer, by detecting the expression level of Nectin-4. The present invention also features double-stranded molecules against the Nectin-4 gene, vectors encoding them, compositions comprising them and methods comprising the step of administering them into a subject, which are useful for treating or preventing cancer. Also, disclosed are methods of identifying candidate compounds for treating and preventing cancer, using the Nectin-4 polypeptide or cells expressing the Nectin-4 gene.

The invention provides an Annexin V fluorescent labeling method for detecting early apoptosis of cells. The specific labeling method comprises the following steps: (1) constructing a pET-22b-SNAP-Annexin V gene fusion plasmid vector; (2) performing prokaryotic expression and purifying pET-22b-SNAP-Annexin V fusion protein; and (3) labeling the fusion protein by using fluorescent small molecules and performing purification. Annexin V protein is one of best phosphatidylserine (PS) binding receptors found at present, shows high selectivity and high binding ability for PS binding, and fluorescently labeled AnnexinV is one of most commonly used reagents for detecting the early apoptosis of the cells. The invention creates the novel method of Annexin V fluorescent labeling, firstly, SNAP tag protein and the Annexin V protein are fused, expressed and purified through the genetic engineering method, then a small molecule fluorescent probe connected to a BG group of a special substrate of the SNAP protein is used to label the fusion protein and label the Annexin V, and the apoptotic cells are detected by cell imaging or flow cytometry. The method has important significance for the researchof the cell apoptosis process.

The invention provides a construction method for an escherichia coli infected monolayer compact bovine mammary epithelial cell model. The cell model is a monolayer compact bovine mammary epithelial cell model infected with escherichia coli is ATCC 25922, and during infection, the transepithelial electrical resistance value of the monolayer compact bovine mammary epithelial cell is 400 [omega]. cm<2>. The escherichia coli infected monolayer compact bovine mammary epithelial cell model provided by the invention can be used for detecting the adhesion rate of the escherichia coli infected monolayer compact bovine mammary epithelial cell and an influence of the escherichia coli infected monolayer compact bovine mammary epithelial cell for the expression of bovine mammary epithelial cell tight junction protein, and can be widely applied to related fields, including the screening of an injury mechanism of the escherichia coli induced mastitis for mammary tissues and mammary epithelial cells,and an antibiotic substitute.

The invention provides a recombinant S protein, a recombinant plasmid and a recombinant bacterium of a novel coronavirus and application of the recombinant S protein, the recombinant plasmid and the recombinant bacterium in preparation of an exosome drug or an exosome vaccine, and relates to the technical field of vaccines. According to the invention, the recombinant S protein comprises a subunit S1 and a subunit S2 of a spike protein S; the S1 protein and the S2 protein are connected through utilizing a linker to form the recombinant S protein; all the components are mutually coordinated and supplemented; and the recombinant S protein has good immunogenicity, safety and biological activity and can induce an organism to generate an effective antibody, so that the growth of the novel coronavirus is inhibited, and the infection of the novel coronavirus can be effectively prevented. According to the invention, the recombinant S protein is electrically transferred into an exosome by adopting an artificial exosome carrying form, so that the pharmacokinetic and pharmacodynamic characteristics of a carried therapeutic agent can be improved, thereby enhancing the therapeutic effect and meanwhile, reducing the adverse toxicity and side effects; and the recombinant S protein has wide cell adhesion molecules and is beneficial for penetrating a biological barrier.

Methods for diagnosing Alzheimer's Disease by detection of fragments of nectin-1 are described. Nectin-1 is shown to be a substrate for proteases associated with the onset of Alzheimer's Disease, including α-secretase, γ-secretase and BACE1 or a BACE1-like protease. The fragments produced by the action of these and other proteases on Nectin-1 can be used to diagnosis Alzheimer's Disease or a predilection towards Alzheimer's Disease.

The invention discloses effect of connexin Panx1 in preparation of a medicine for preventing and treating neuropathic pain, and belongs to the technical field of biological medicines. Main expression Panx1 in Schwann cells is determined, and the expression quantity of the Panx1 can be remarkably increased due to chronic neuropathic pathological injury; an inhibitor and a mimic peptide of the Panx1 can remarkably inhibit mechanical pain and heat pain caused by chronic neuropathic pathological injury of sciatic nerves, and meanwhile, a Panx1 inhibitor probenecid can remarkably inhibit the expression of the Panx1 caused by injury. Therefore, powerful basic research evidence is provided for treating patients with chronic neuropathic pathological pain by clinically utilizing the Panx1 inhibitor in the future.

The invention relates to the field of medical biology, and provides a separation and amplification method and application of human dental pulp stem cells. The separation and amplification method comprises the following steps: S1, taking human dental pulp tissue, cutting the human dental pulp tissue into pieces, and adding collagenase I, hyaluronidase and dispase II for digestion to obtain digestedtissue and cell suspension; S2, filtering the digested tissue and cell suspension by using a filter screen, centrifuging the filtrate, and taking cell precipitate to obtain human dental pulp stem cells; and S3, inoculating the human dental pulp stem cells into a culture dish pre-coated with human fibronectin, adding a culture solution for culture, and performing subculture when convergence rate reaches 70-80%. The method has a short time for cell adherence, number of cells cultured to the 10th day of at least 4.5x105, high cell purity, positive expression rate of dental pulp stem cell surfacemarkers CD73, CD90 and CD105 above 99%, and negative index expression rate lower than 1.2%.

The present invention relates to diagnostic and prognostic methods and kits for assessing chronic inflammation and associated immune-suppression. More particularly, the invention relates to the use of SNX9 (sorting nexin 9 protein) as a biomarker for chronic inflammation and associated immune-suppression, specifically, in subjects suffering from chronic inflammatory conditions. The invention further provides a prognostic tool for detecting regression or recurrence of the diseases and a powerful tool for assessing efficacy of a treatment. The present invention further provides SNX9 as an immunomodulator and therefore relates to methods for treating immune-related disorders by modulating SNX9 expression.

The invention provides application of an exosome derived from mesenchymal stem cells in preparation of a medicine for treating acute lung injury caused by sulfur mustard. The invention particularly relates to separation of bone marrow mesenchymal stem cell supernate to obtain exosomes and application of the exosomes to acute lung injury caused by sulfur mustard. The exosomes can significantly improve survival rate of experimental animals and improve activity of lung cells under the exposure of sulfur mustard, improves changes in lung tight junction proteins caused by sulfur mustard, and resists lung injury effect of sulfur mustard. Therefore, the invention provides a new treatment approach for acute lung injury caused by sulfur mustard.

The present invention relates to multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, or a claudin-18.2. In particular. Specifically, the present invention describes multispecific binding proteins that bind to the NKG2D receptor, CD16 and a tumor-associated antigen selected from the group consisting of carbonic anhydrase 9 (CAIX), calcitonin 1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2, as well as pharmaceutical compositions and methods of treatment useful in the treatment of cancer.

The invention discloses a preparation method and an application of a stem cell supernate rich in VEGF and FGF. The preparation method comprises the following steps: preparing umbilical cord stem cells, over-expressing human the vascular endothelial cell growth factor (VEGF) and the human fibroblast growth factor (FGF) through a molecular cloning technology, then carrying out amplification passage,and collecting the obtained cell culture supernate to obtain the finished stem cell supernate. The supernate can be applied to repair treatment of diabetic foot gangrene wounds with limb ischemia. The preparation method has the advantages o reasonable process design, simplicity in operation, and high feasibility, and the obtained supernate contains the over-expressed VEGF and FGF, also contains human epidermal cell growth factors, human keratinocyte growth factors, human platelet-like derivative growth factors, fibronectin, immune factors and other factors, can be applied to repair treatmentof diabetic foot extremity ischemia, provides a new way for application of the stem cells to medical transformation, and has high practicability.